Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 6/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | PTGES | O14684 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.39 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16691530 | 0.81 | HSP90AA1 (0.43) | CYP19A1MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL8308233 | 0.79 | CHRM4 (0.47) | MEN1KMT2AALDH1A1MAPTCYP3A4 | |
| SCHEMBL8182657 | 0.78 | MEN1 (0.46) | CYP19A1MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL8172174 | 0.77 | CYP19A1 (0.45) | CYP19A1MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL5474066 | 0.76 | IDO1 (0.58) | ALDH1A1LMNA | |
| SCHEMBL8312961 | 0.75 | HSP90AA1 (0.46) | MEN1KMT2AALDH1A1MAPTCYP3A4 | |
| SCHEMBL16691532 | 0.75 | HSP90AA1 (0.44) | MEN1KMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL6478814 | 0.75 | HSP90AA1 (0.47) | MEN1KMT2AALDH1A1MAPTHSP90AA1 | |
| SCHEMBL7509358 | 0.75 | HSP90AA1 (0.47) | MEN1KMT2AALDH1A1MAPTHSP90AA1 | |
| SCHEMBL30073945 | 0.75 | HSP90AA1 (0.47) | MEN1KMT2AALDH1A1MAPTHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2846794-B1 | BICYCLIC SULFONE COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | MERCK SHARP & DOHME (US) | 2017-11-01 | — | — | EP | disclosed |
| EP-2846794-B1 | BICYCLIC SULFONE COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | MERCK SHARP & DOHME (US) | 2017-11-01 | — | — | EP | disclosed |
| US-9266827-B2 | Bicyclic sulfone compounds for inhibition of RORgamma activity and the treatment of disease | MERCK SHARP & DOHME CORP. (US) | 2016-02-23 | — | — | US | disclosed |
| US-20150126493-A1 | BICYCLIC SULFONE COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | MERCK SHARP & DOHME LLC | 2015-05-07 | — | — | US | disclosed |
| US-20150126493-A1 | BICYCLIC SULFONE COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | MERCK SHARP & DOHME LLC | 2015-05-07 | — | — | US | disclosed |
| EP-2846794-A1 | BICYCLIC SULFONE COMPOUNDS FOR INHIBITION OF RORy ACTIVITY AND THE TREATMENT OF DISEASE | Merck Sharp & Dohme Corp. (US) | 2015-03-18 | — | — | EP | disclosed |
| WO-2013169588-A1 | BICYCLIC SULFONE COMPOUNDS FOR INHIBITION OF RORy ACTIVITY AND THE TREATMENT OF DISEASE | MERCK SHARP & DOHME CORP. (US) | 2013-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150126493-A1 | BICYCLIC SULFONE COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | RORC, RORB, RORA | CYP19A1 128/4885MEN1 4716/4885KMT2A 1780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.